Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | ASGR1 | P07306 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2503399 | 0.87 | KMT2A (0.47) | KMT2ACA2CA1ASGR1ALDH1A1 | |
| SCHEMBL12391259 | 0.87 | KMT2A (0.47) | KMT2ACA2CA1ASGR1ALDH1A1 | |
| SCHEMBL8823006 | 0.87 | KMT2A (0.47) | KMT2ACA2CA1ASGR1ALDH1A1 | |
| SCHEMBL16864092 | 0.87 | KMT2A (0.47) | KMT2ACA2CA1ASGR1ALDH1A1 | |
| SCHEMBL16367194 | 0.87 | KMT2A (0.47) | KMT2ACA2CA1ASGR1ALDH1A1 | |
| SCHEMBL10209192 | 0.83 | ALDH1A1 (0.40) | KMT2ACA2CA1ASGR1ALDH1A1 | |
| SCHEMBL12560770 | 0.81 | MAPK1 (0.40) | KMT2ACA2CA1ASGR1ALDH1A1 | |
| SCHEMBL25509870 | 0.80 | CA2 (0.35) | CA2CA1CA9 | |
| SCHEMBL25510322 | 0.80 | CA2 (0.35) | CA2CA1CA9 | |
| SCHEMBL12560739 | 0.78 | ALDH1A1 (0.37) | KMT2ACA2CA1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150050282-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X | INSTITUT PASTEUR (FR) | 2015-02-19 | — | — | US | disclosed |
| US-8815239-B2 | Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X | INSTITUT PASTEUR (FR) | 2014-08-26 | — | — | US | disclosed |
| US-20100239584-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X | INSTITUT PASTEUR (FR) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239584-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X | ST3GAL3, SI, STT3A | KMT2A 3430/4885CA2 3218/4885CA1 1299/4885 |
| US-20150050282-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X | ST3GAL3, SI, STT3A | KMT2A 3430/4885CA2 3218/4885CA1 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.